CONVERT Trial Shows No Advantage to Once-Daily Radiotherapy for LS-SCLC
The phase 3 CONVERT study suggests that twice-daily radiotherapy remains the standard for limited-stage small cell lung cancer due to its effectiveness and lower associated toxicity compared to the once-daily approach.